

David Dingli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1186019/publications.pdf>

Version: 2024-02-01

538
papers

20,073
citations

13827

67
h-index

15683

125
g-index

548
all docs

548
docs citations

548
times ranked

14102
citing authors

#	ARTICLE	IF	CITATIONS
1	Kidney Transplantation in Patients With Monoclonal Gammopathy of Renal Significance (MGRS)â€™Associated Lesions: A Case Series. American Journal of Kidney Diseases, 2022, 79, 202-216.	2.1	9
2	Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia, 2022, 36, 801-808.	3.3	43
3	Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. Leukemia, 2022, 36, 873-876.	3.3	12
4	Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis. Leukemia, 2022, 36, 1058-1065.	3.3	3
5	Characteristics and risk factors for thrombosis in <scp>POEMS</scp> syndrome: A retrospective evaluation of 230 patients. American Journal of Hematology, 2022, 97, 209-215.	2.0	5
6	Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome. American Journal of Hematology, 2022, , .	2.0	5
7	The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey. Annals of Hematology, 2022, 101, 251-263.	0.8	19
8	Kidney Transplant Outcomes of Patients With Multiple Myeloma. Kidney International Reports, 2022, 7, 752-762.	0.4	7
9	A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer Journal, 2022, 12, 21.	2.8	30
10	Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab. Leukemia, 2022, 36, 1426-1428.	3.3	7
11	Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation. American Journal of Hematology, 2022, , .	2.0	2
12	Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio â€™100. Leukemia, 2022, 36, 1429-1431.	3.3	8
13	Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma. Blood Advances, 2022, 6, 2763-2772.	2.5	13
14	Impact of maintenance therapy post autologous stem cell transplantation for multiple myeloma in early and delayed transplant. Bone Marrow Transplantation, 2022, 57, 803-809.	1.3	6
15	Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis. Bone Marrow Transplantation, 2022, , .	1.3	0
16	Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation. Blood Cancer Journal, 2022, 12, 59.	2.8	3
17	Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS). Blood Cancer Journal, 2022, 12, 62.	2.8	6
18	Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation. Leukemia and Lymphoma, 2022, 63, 2422-2427.	0.6	2

#	ARTICLE	IF	CITATIONS
19	Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 274-277.	1.3	1
20	A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis. <i>Kidney International</i> , 2021, 99, 707-715.	2.6	13
21	Computational and systems biology of cancer. <i>Computational and Systems Oncology</i> , 2021, 1, e1005.	1.1	0
22	Outcomes of multiple myeloma patients with $\text{del } 17p$ undergoing autologous stem cell transplantation. <i>American Journal of Hematology</i> , 2021, 96, E35-E38.	2.0	2
23	Characterization and prognostic implication of delayed complete response in AL amyloidosis. <i>European Journal of Haematology</i> , 2021, 106, 354-361.	1.1	4
24	Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide. <i>European Journal of Haematology</i> , 2021, 106, 433-436.	1.1	3
25	Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents. <i>Bone Marrow Transplantation</i> , 2021, 56, 1144-1150.	1.3	15
26	Implications of detecting serum monoclonal protein by MASS-Fix following stem cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2021, 193, 380-385.	1.2	21
27	Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, 330-337.	2.0	13
28	Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2021, 56, 928-935.	1.3	5
29	Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 309.e1-309.e5.	0.6	1
30	Retroperitoneal involvement with light chain amyloidosis- case series and literature review. <i>Leukemia and Lymphoma</i> , 2021, 62, 316-322.	0.6	2
31	Systemic amyloidosis from A (AA) to T (ATTR): a review. <i>Journal of Internal Medicine</i> , 2021, 289, 268-292.	2.7	133
32	Preclinical development of CD126 CAR-T cells with broad antitumor activity. <i>Blood Cancer Journal</i> , 2021, 11, 3.	2.8	16
33	Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. <i>Leukemia</i> , 2021, 35, 1428-1437.	3.3	8
34	Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. <i>Mayo Clinic Proceedings</i> , 2021, 96, 677-687.	1.4	16
35	MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. <i>Blood Cancer Journal</i> , 2021, 11, 50.	2.8	25
36	Acute Acquired Fanconi Syndrome in Multiple Myeloma After Hematopoietic Stem Cell Transplantation. <i>Kidney International Reports</i> , 2021, 6, 857-864.	0.4	5

#	ARTICLE	IF	CITATIONS
37	Multistage feedback-driven compartmental dynamics of hematopoiesis. <i>IScience</i> , 2021, 24, 102326.	1.9	5
38	Efficacy of Daratumumab-Based Regimens for the Treatment of Plasma Cell Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 355-360.	0.2	5
39	Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design. <i>Leukemia</i> , 2021, 35, 3604-3607.	3.3	8
40	Assessment of fixed-duration therapies for treatment of Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2021, 96, 945-953.	2.0	12
41	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1546-1577.	1.4	32
42	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 451-460.e2.	0.2	9
43	Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 589.e1-589.e6.	0.6	3
44	Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis. <i>Leukemia and Lymphoma</i> , 2021, 62, 3011-3018.	0.6	2
45	Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. <i>American Journal of Hematology</i> , 2021, 96, 1131-1136.	2.0	21
46	Quantitative imaging and dynamics of tumor therapy with viruses. <i>FEBS Journal</i> , 2021, 288, 6273-6285.	2.2	2
47	Epstein Barr Virus "Negative Lymphoplasmacytic Proliferation Limited to the Renal Allograft: A Unique Presentation of a Rare Disease. <i>Kidney International Reports</i> , 2021, 6, 2223-2227.	0.4	0
48	Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2021, 195, 210-216.	1.2	12
49	The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM). <i>Blood Cancer Journal</i> , 2021, 11, 158.	2.8	9
50	The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 770.e1-770.e7.	0.6	6
51	Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort. <i>American Journal of Hematology</i> , 2021, 96, 446-454.	2.0	8
52	Prognostic significance of acquired 1q22 gain in multiple myeloma. <i>American Journal of Hematology</i> , 2021, . .	2.0	6
53	"Real-Life" Data of the Efficacy and Safety of Belantamab Mafodotin in Relapsed Multiple Myeloma- the Mayo Clinic Experience. <i>Blood</i> , 2021, 138, 1639-1639.	0.6	3
54	Tracking Daratumumab Clearance Using Mass Spectrometric Approaches: Implications on M Protein Monitoring and Reusing Daratumumab. <i>Blood</i> , 2021, 138, 2707-2707.	0.6	0

#	ARTICLE	IF	CITATIONS
55	An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 (VSV-IFN β -NIS). <i>Blood</i> , 2021, 138, 1333-1333.	0.6	0
56	Prognostic Role of IL-6 in POEMS Syndrome. <i>Blood</i> , 2021, 138, 2700-2700.	0.6	0
57	Monoclonal Proteinuria Predicts Progression Risk in Asymptomatic Multiple Myeloma with a Free Light Chain Ratio \geq 100. <i>Blood</i> , 2021, 138, 1617-1617.	0.6	0
58	Second Line Treatment Strategies in Multiple Myeloma: A Referral-Center Experience. <i>Blood</i> , 2021, 138, 819-819.	0.6	1
59	Amyloidosis Composite Response Score Incorporating the Depth of Organ Response. <i>Blood</i> , 2021, 138, 3805-3805.	0.6	0
60	Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. <i>Blood Cancer Journal</i> , 2021, 11, 186.	2.8	8
61	Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma. <i>Blood</i> , 2021, 138, 1750-1750.	0.6	2
62	Outcomes Following Biochemical or Clinical Progression in Patients with Multiple Myeloma. <i>Blood</i> , 2021, 138, 3760-3760.	0.6	1
63	Impact of Achieving an Early Complete Response in Multiple Myeloma and Predictors of Subsequent Outcome. <i>Blood</i> , 2021, 138, 3773-3773.	0.6	0
64	Prognostic Factors for Early (\leq 2 years) and Late ($>$ 5 years) Relapse in Multiple Myeloma- Pivotal Role of Cytogenetic Changes. <i>Blood</i> , 2021, 138, 3761-3761.	0.6	0
65	Outcomes of Triple Class (Proteasome Inhibitor, IMiDs and Monoclonal Antibody) Refractory Patients with Multiple Myeloma. <i>Blood</i> , 2021, 138, 1632-1632.	0.6	0
66	Prognostic Impact of CD3 Count in Apheresis Collection in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant. <i>Blood</i> , 2021, 138, 3774-3774.	0.6	1
67	The Prognostic Utility of Serial MASS-FIX in Multiple Myeloma. <i>Blood</i> , 2021, 138, 1619-1619.	0.6	0
68	Assessing the Prognostic Utility of the Mayo 2018 and IMWG 2020 Smoldering Multiple Myeloma Risk Stratification Scores When Applied Post Diagnosis. <i>Blood</i> , 2021, 138, 543-543.	0.6	0
69	Factors Associated with Renal Impairment at Diagnosis in Multiple Myeloma with Survival Trends over Last Two Decades. <i>Blood</i> , 2021, 138, 1630-1630.	0.6	0
70	Pilot Implementation of Remote Patient Monitoring Program for Outpatient Management of CAR-T Cell Therapy. <i>Blood</i> , 2021, 138, 568-568.	0.6	4
71	Mortality Trends in Multiple Myeloma after the Introduction of Novel Therapies in the United States. <i>Blood</i> , 2021, 138, 119-119.	0.6	0
72	The Impact of the Central Carbon Energy Metabolism Transcriptome in the Pathogenesis and Outcomes of Multiple Myeloma. <i>Blood</i> , 2021, 138, 2650-2650.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Single Cell Transcriptome Profile of Myeloma and Immune Cell Characteristics in Patients with Durable Response Post CART. <i>Blood</i> , 2021, 138, 3838-3838.	0.6	1
74	“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience. <i>Blood Cancer Journal</i> , 2021, 11, 196.	2.8	28
75	Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 13-16.	1.4	25
76	Pyoderma gangrenosum in hematologic malignancies: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1346-1359.	0.6	38
77	Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. <i>British Journal of Haematology</i> , 2020, 188, 394-403.	1.2	41
78	Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma. <i>American Journal of Hematology</i> , 2020, 95, E8-E10.	2.0	10
79	Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. <i>American Journal of Hematology</i> , 2020, 95, 4-9.	2.0	14
80	Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 53-56.	0.2	8
81	Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. <i>American Journal of Hematology</i> , 2020, 95, 310-315.	2.0	37
82	Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity. <i>American Journal of Hematology</i> , 2020, 95, E60-E62.	2.0	4
83	Impact of MYD88 ^{L265P} mutation status on histological transformation of Waldenström Macroglobulinemia. <i>American Journal of Hematology</i> , 2020, 95, 274-281.	2.0	33
84	Revisiting complete response in light chain amyloidosis. <i>Leukemia</i> , 2020, 34, 1472-1475.	3.3	15
85	Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. <i>Leukemia</i> , 2020, 34, 1135-1143.	3.3	29
86	Colon perforation in multiple myeloma patients – A complication of high-dose steroid treatment. <i>Cancer Medicine</i> , 2020, 9, 8895-8901.	1.3	3
87	Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 6581-6588.	3.2	32
88	Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 95.	2.8	3
89	Predictors of short-term survival in Waldenström Macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 2975-2979.	0.6	2
90	Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio. <i>American Journal of Hematology</i> , 2020, 95, 1280-1287.	2.0	17

#	ARTICLE	IF	CITATIONS
91	Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. <i>Blood Advances</i> , 2020, 4, 3509-3519.	2.5	58
92	Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. <i>Blood Cancer Journal</i> , 2020, 10, 82.	2.8	59
93	Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. <i>Blood Cancer Journal</i> , 2020, 10, 124.	2.8	12
94	Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. <i>Bone Marrow Transplantation</i> , 2020, 55, 2132-2137.	1.3	8
95	Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1402-1405.	2.0	4
96	The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?. <i>Blood Cancer Journal</i> , 2020, 10, 52.	2.8	8
97	Venetoclax for the treatment of translocation (11;14) AL amyloidosis. <i>Blood Cancer Journal</i> , 2020, 10, 55.	2.8	36
98	“Direct to Drug” screening as a precision medicine tool in multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 54.	2.8	20
99	Venetoclax in a Patient With Light Chain Deposition Disease Secondary to MGRS That Progressed After Kidney Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e488-e491.	0.2	3
100	Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2020, 55, 1297-1304.	1.3	5
101	Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. <i>American Journal of Hematology</i> , 2020, 95, 637-642.	2.0	12
102	Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. <i>American Journal of Hematology</i> , 2020, 95, 1170-1179.	2.0	19
103	Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis. <i>Blood Cancer Journal</i> , 2020, 10, 20.	2.8	26
104	Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. <i>Blood Cancer Journal</i> , 2020, 10, 4.	2.8	18
105	Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 596-601.	0.2	15
106	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone for Treatment of Previously Untreated Light Chain Amyloidosis. <i>Blood</i> , 2020, 136, 52-53.	0.6	4
107	MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients. <i>Blood</i> , 2020, 136, 48-49.	0.6	2
108	Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2020, 136, 36-37.	0.6	4

#	ARTICLE	IF	CITATIONS
109	Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , 2020, 136, 30-31.	0.6	4
110	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). <i>Blood</i> , 2020, 136, 7-8.	0.6	1
111	Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM). <i>Blood</i> , 2020, 136, 12-13.	0.6	3
112	Presence of a Measurable M-Spike before Autologous Stem Cell Transplantation Is Associated with Shorter Survival in Patients with Light Chain Amyloidosis. <i>Blood</i> , 2020, 136, 22-23.	0.6	1
113	Comparison of Conventional Xrays with CT Based Approaches for Detection of Lytic Lesions in Multiple Myeloma. <i>Blood</i> , 2020, 136, 27-28.	0.6	0
114	A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders. <i>Blood</i> , 2020, 136, 44-45.	0.6	0
115	Prognostic Impact of PET Findings Post-Transplant in Multiple Myeloma. <i>Blood</i> , 2020, 136, 15-16.	0.6	0
116	Treatments and Outcomes of Newly Diagnosed Multiple Myeloma Patients > 75 Years Old: A Retrospective Analysis. <i>Blood</i> , 2020, 136, 14-15.	0.6	0
117	Prognostic Restaging after Treatment Initiation in Patients with AL Amyloidosis. <i>Blood</i> , 2020, 136, 6-7.	0.6	0
118	Work Productivity Loss and Quality of Life in Paroxysmal Nocturnal Hemoglobinuria Among Patients Receiving C5 Inhibitors in the United States. <i>Blood</i> , 2020, 136, 3-3.	0.6	2
119	Outcomes of Multiple Myeloma Patients with Del 17p Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 21-22.	0.6	0
120	A 3-Question Symptom Assessment Score Can Predict Outcomes in Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , 2020, 136, 21-22.	0.6	0
121	Autologous Stem Cell Transplantation for Multiple Myeloma Patients Aged ≥ 75 Treated with Novel Agents. <i>Blood</i> , 2020, 136, 12-13.	0.6	0
122	Unmet Needs in AL Amyloidosis: Outcomes in the Modern Era Among the Highest Risk, Newly Diagnosed AL Amyloidosis Patients. <i>Blood</i> , 2020, 136, 31-32.	0.6	1
123	Retroperitoneal Involvement of Light Chain Amyloidosis-Case Series and Literature Review. <i>Blood</i> , 2020, 136, 37-38.	0.6	0
124	Efficacy of Daratumumab (Dara)-Based Regimens for the Treatment of Plasma Cell Leukemia (PCL). <i>Blood</i> , 2020, 136, 29-30.	0.6	2
125	Decreased Cardiac Ejection Fraction Is Associated with Worse Survival in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 41-42.	0.6	0
126	Clinical Burden of Paroxysmal Nocturnal Hemoglobinuria Among Patients Receiving C5 Inhibitors in the United States. <i>Blood</i> , 2020, 136, 2-2.	0.6	0

#	ARTICLE	IF	CITATIONS
127	Waldenström Macroglobulinemia in the Very Elderly (≥75 years): Clinical Characteristics and Outcomes. <i>Blood</i> , 2020, 136, 44-45.	0.6	8
128	Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 587-594.	1.3	9
129	Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response. <i>Bone Marrow Transplantation</i> , 2019, 54, 442-447.	1.3	7
130	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. <i>Bone Marrow Transplantation</i> , 2019, 54, 353-367.	1.3	81
131	Oral Selinexor + Dexamethasone for Triple-Class Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019, 381, 727-738.	13.9	460
132	Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. <i>British Journal of Haematology</i> , 2019, 187, 588-594.	1.2	40
133	Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 101-102.	1.4	9
134	Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. <i>American Journal of Hematology</i> , 2019, 94, 1020-1026.	2.0	36
135	Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. <i>American Journal of Hematology</i> , 2019, 94, 1066-1071.	2.0	14
136	The invasion of de-differentiating cancer cells into hierarchical tissues. <i>PLoS Computational Biology</i> , 2019, 15, e1007167.	1.5	16
137	Comparative analysis of staging systems in AL amyloidosis. <i>Leukemia</i> , 2019, 33, 811-814.	3.3	22
138	Oncolytic Measles Virotherapy and Opposition to Measles Vaccination. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1834-1839.	1.4	9
139	The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 2039-2050.	1.3	9
140	Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1520-1525.	2.0	9
141	How many samples are needed to infer truly clonal mutations from heterogenous tumours?. <i>BMC Cancer</i> , 2019, 19, 403.	1.1	21
142	Metformin inhibits IL-6 signaling by decreasing IL-6R expression on multiple myeloma cells. <i>Leukemia</i> , 2019, 33, 2695-2709.	3.3	52
143	In vitro and in silico multidimensional modeling of oncolytic tumor virotherapy dynamics. <i>PLoS Computational Biology</i> , 2019, 15, e1006773.	1.5	19
144	Natural history of multiple myeloma with de novo del(17p). <i>Blood Cancer Journal</i> , 2019, 9, 32.	2.8	38

#	ARTICLE	IF	CITATIONS
145	Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function. <i>Bone Marrow Transplantation</i> , 2019, 54, 1775-1779.	1.3	9
146	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. <i>American Journal of Hematology</i> , 2019, 94, 751-756.	2.0	15
147	InÂVivo Imaging of Oncolytic Measles Virus Propagation with Single-Cell Resolution. <i>Molecular Therapy - Oncolytics</i> , 2019, 12, 68-78.	2.0	11
148	Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. <i>Leukemia</i> , 2019, 33, 1268-1272.	3.3	7
149	Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis. <i>American Journal of Hematology</i> , 2019, 94, E141-E143.	2.0	17
150	A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometryâ€œVerified Typing. <i>Mayo Clinic Proceedings</i> , 2019, 94, 472-483.	1.4	59
151	Impact of acquired del(17p) in multiple myeloma. <i>Blood Advances</i> , 2019, 3, 1930-1938.	2.5	41
152	Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multiâ€œparametric flow cytometry method. <i>American Journal of Hematology</i> , 2019, 94, 424-430.	2.0	11
153	Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e108-e111.	2.0	20
154	Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1077-1081.	1.3	7
155	Primary systemic amyloidosis in patients with WaldenstrÃ¶m macroglobulinemia. <i>Leukemia</i> , 2019, 33, 790-794.	3.3	28
156	Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. <i>Leukemia</i> , 2019, 33, 730-738.	3.3	20
157	T-cell large granular lymphocytic leukemia and plasma cell disorders. <i>Haematologica</i> , 2019, 104, e108-e110.	1.7	9
158	Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. <i>Leukemia</i> , 2019, 33, 527-531.	3.3	36
159	Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. <i>Leukemia</i> , 2019, 33, 531-536.	3.3	72
160	Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study. <i>Blood</i> , 2019, 134, 1872-1872.	0.6	3
161	Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States. <i>Blood</i> , 2019, 134, 72-72.	0.6	2
162	Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis. <i>Blood</i> , 2019, 134, 4334-4334.	0.6	1

#	ARTICLE	IF	CITATIONS
163	Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucef Therapy for Lymphoma. <i>Blood</i> , 2019, 134, 4106-4106.	0.6	6
164	A Prospective Pilot Study of Ixazomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed or Relapsed/Refractory POEMS Syndrome. <i>Blood</i> , 2019, 134, 1846-1846.	0.6	2
165	Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas. <i>Blood</i> , 2019, 134, 3140-3140.	0.6	13
166	Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma. <i>Blood</i> , 2019, 134, 4386-4386.	0.6	2
167	Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019, 134, 864-864.	0.6	13
168	Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma. <i>Blood</i> , 2019, 134, 1905-1905.	0.6	2
169	Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2019, 94, 455-464.	1.4	16
170	Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma. <i>Blood</i> , 2019, 134, 4505-4505.	0.6	0
171	Hypovitaminosis D Is Prevalent in Patients with Renal AL Amyloidosis and Associated with Non-t(11;14). <i>Blood</i> , 2019, 134, 5523-5523.	0.6	0
172	Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. <i>Blood</i> , 2019, 134, 1532-1532.	0.6	0
173	Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition. <i>Blood</i> , 2019, 134, 3080-3080.	0.6	0
174	Determinants of Clinical Trial Participation and Impact on Survival Outcomes Among Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019, 134, 5833-5833.	0.6	0
175	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma. <i>Blood</i> , 2019, 134, 1904-1904.	0.6	0
176	Increased Mean Corpuscular Volume Is an Independent Predictor for Worse Overall Survival in Patients with Newly Diagnosed Light Chain Amyloidosis. <i>Blood</i> , 2019, 134, 5532-5532.	0.6	0
177	Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant. <i>Blood</i> , 2019, 134, 3171-3171.	0.6	1
178	A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH. <i>Blood</i> , 2019, 134, 1800-1800.	0.6	1
179	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019, 134, 2197-2197.	0.6	0
180	Use of Maintenance Therapy Post Autologous Stem Cell Transplantation Outside of Clinical Trial Setting for Multiple Myeloma: Single Institution Experience. <i>Blood</i> , 2019, 134, 2013-2013.	0.6	0

#	ARTICLE	IF	CITATIONS
181	Clinical Outcomes and Cytogenetic Features of Primary Plasma Cell Leukemia (pPCL) in the Era of Novel Agent Induction Therapy. <i>Blood</i> , 2019, 134, 5490-5490.	0.6	1
182	Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. <i>Leukemia</i> , 2018, 32, 1421-1426.	3.3	8
183	Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. <i>Leukemia</i> , 2018, 32, 2240-2249.	3.3	64
184	Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. <i>Haematologica</i> , 2018, 103, 1229-1234.	1.7	10
185	Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2127-2132.	2.0	21
186	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. <i>Annals of Hematology</i> , 2018, 97, 1417-1425.	0.8	71
187	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. <i>Leukemia</i> , 2018, 32, 1811-1815.	3.3	28
188	Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2018, 53, 326-333.	1.3	4
189	Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2018, 93, 56-58.	1.4	16
190	Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation. <i>British Journal of Haematology</i> , 2018, 182, 71-77.	1.2	15
191	Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 86-92.	1.4	57
192	Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. <i>Blood Cancer Journal</i> , 2018, 8, 26.	2.8	92
193	Natural history of t(11;14) multiple myeloma. <i>Leukemia</i> , 2018, 32, 131-138.	3.3	67
194	Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 179-186.	2.0	49
195	MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018, 93, 187-194.	2.0	57
196	Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL). <i>American Journal of Hematology</i> , 2018, 93, 17-22.	2.0	11
197	Pomalidomide+dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial. <i>Leukemia</i> , 2018, 32, 719-728.	3.3	13
198	Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation. <i>Leukemia</i> , 2018, 32, 712-718.	3.3	27

#	ARTICLE	IF	CITATIONS
199	Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains. <i>Leukemia</i> , 2018, 32, 729-735.	3.3	44
200	Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 155-161.	1.3	8
201	Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2018, 36, 859-866.	0.8	140
202	Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. <i>Journal of Clinical Oncology</i> , 2018, 36, 1323-1329.	0.8	100
203	Replicative cellular age distributions in compartmentalized tissues. <i>Journal of the Royal Society Interface</i> , 2018, 15, 20180272.	1.5	10
204	Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 106.	2.8	16
205	Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 116.	2.8	64
206	Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. <i>Blood Cancer Journal</i> , 2018, 8, 125.	2.8	29
207	Utility and prognostic value of ¹⁸ F- β FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 1518-1523.	2.0	19
208	Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. <i>Blood Advances</i> , 2018, 2, 769-776.	2.5	23
209	HIV-1 Activation of Innate Immunity Depends Strongly on the Intracellular Level of TREX1 and Sensing of Incomplete Reverse Transcription Products. <i>Journal of Virology</i> , 2018, 92, .	1.5	29
210	Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2360-2364.	2.0	14
211	Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2157-2159.	2.0	8
212	Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 70.	2.8	18
213	Serum free light chain measurements to reduce 24h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. <i>American Journal of Hematology</i> , 2018, 93, 1207-1210.	2.0	3
214	Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis. <i>Circulation: Cardiovascular Imaging</i> , 2018, 11, e006588.	1.3	51
215	<i>In Vivo</i> Estimation of Oncolytic Virus Populations within Tumors. <i>Cancer Research</i> , 2018, 78, 5992-6000.	0.4	16
216	Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018, 93, 1384-1393.	2.0	24

#	ARTICLE	IF	CITATIONS
217	A Patient With Hereditary ATTR and a Novel AGel p.Ala578Pro Amyloidosis. Mayo Clinic Proceedings, 2018, 93, 1678-1682.	1.4	18
218	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer Journal, 2018, 8, 59.	2.8	171
219	Evolutionary dynamics of paroxysmal nocturnal hemoglobinuria. PLoS Computational Biology, 2018, 14, e1006133.	1.5	14
220	Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 304-304.	0.6	10
221	Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM. Blood, 2018, 132, 598-598.	0.6	17
222	Oncolytic virotherapy - in vivo veritas. Oncotarget, 2018, 9, 36254-36255.	0.8	1
223	Prognostic Value of Clone Size in Paroxysmal Nocturnal Hemoglobinuria (PNH) for Thrombotic Events in Untreated Patients in the International PNH Registry. Blood, 2018, 132, 1038-1038.	0.6	0
224	Long-Term Survivorship with Active Multiple Myeloma. Blood, 2018, 132, 1912-1912.	0.6	0
225	Comparative Analysis of Staging Systems in AL Amyloidosis. Blood, 2018, 132, 3228-3228.	0.6	0
226	Impact of Acquired Del(17p) in Patients with Multiple Myeloma. Blood, 2018, 132, 4449-4449.	0.6	0
227	Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience. Blood, 2018, 132, 2147-2147.	0.6	0
228	Long-Term AL Amyloidosis Survivors Among Non-Selected Referral Population. Blood, 2018, 132, 3226-3226.	0.6	0
229	Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting. Blood, 2018, 132, 1606-1606.	0.6	1
230	Salvage Autologous Stem Cell Transplantation in Multiple Myeloma: Investigating the Impact of Pre-Transplant Therapy. Blood, 2018, 132, 4613-4613.	0.6	0
231	Mass Spectrometry to Measure Response in Immunoglobulin Light Chain Amyloidosis (AL). Blood, 2018, 132, 4502-4502.	0.6	0
232	Prognostic Restaging at the Time of 2nd-Line Therapy in Patients with AL Amyloidosis. Blood, 2018, 132, 5594-5594.	0.6	0
233	Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy. Blood, 2018, 132, 3227-3227.	0.6	0
234	Plasma Cell Disorders in Patients with Age-Related Transthyretin (ATTRwt) Amyloidosis. Blood, 2018, 132, 5610-5610.	0.6	0

#	ARTICLE	IF	CITATIONS
235	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). <i>Blood</i> , 2018, 132, 3268-3268.	0.6	0
236	Three Decades of Autologous Stem Cell Transplantation for Myeloma; Trends in Early Mortality and Survival. <i>Blood</i> , 2018, 132, 3436-3436.	0.6	0
237	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018, 132, 2884-2884.	0.6	1
238	T Cell Large Granular Lymphocytic Leukemia and Co-Existing Plasma Cell Disorders. <i>Blood</i> , 2018, 132, 5368-5368.	0.6	1
239	Characterization of Exceptional Responders to Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , 2018, 132, 4615-4615.	0.6	0
240	Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma. <i>Blood</i> , 2018, 132, 3160-3160.	0.6	2
241	Prognosis of Patients with Waldenström Macroglobulinemia: A Simplified Model. <i>Blood</i> , 2018, 132, 4152-4152.	0.6	1
242	Patient-Reported Outcome Driven Case Management System for Hematology – a Prospective Study. <i>Blood</i> , 2018, 132, 719-719.	0.6	1
243	Therapy for relapsed multiple myeloma. <i>Panminerva Medica</i> , 2018, 60, 174-184.	0.2	1
244	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. <i>Leukemia</i> , 2017, 31, 92-99.	3.3	30
245	Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2017, 58, 308-315.	0.6	16
246	Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 598-605.	2.0	47
247	Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. <i>Annals of Medicine</i> , 2017, 49, 545-551.	1.5	45
248	Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma. <i>Blood Cancer Journal</i> , 2017, 7, e528-e528.	2.8	39
249	Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. <i>American Journal of Hematology</i> , 2017, 92, 435-440.	2.0	16
250	The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. <i>Blood</i> , 2017, 129, 82-87.	0.6	50
251	Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. <i>Blood</i> , 2017, 129, 2111-2119.	0.6	249
252	Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival. <i>Bone Marrow Transplantation</i> , 2017, 52, 1126-1132.	1.3	30

#	ARTICLE	IF	CITATIONS
253	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 40-41.	1.4	4
254	Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 44-45.	1.4	1
255	Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosis. <i>Journal of Internal Medicine</i> , 2017, 281, 611-619.	2.7	15
256	Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma. <i>Leukemia</i> , 2017, 31, 2791-2798.	3.3	120
257	Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. <i>Leukemia</i> , 2017, 31, 1562-1569.	3.3	92
258	Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2017, 7, e569-e569.	2.8	8
259	The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. <i>American Journal of Hematology</i> , 2017, 92, E507-E512.	2.0	5
260	Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. <i>American Journal of Hematology</i> , 2017, 92, 668-673.	2.0	75
261	Detecting truly clonal alterations from multi-region profiling of tumours. <i>Scientific Reports</i> , 2017, 7, 44991.	1.6	24
262	Therapy for Relapsed Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2017, 92, 578-598.	1.4	115
263	Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis. <i>American Journal of Hematology</i> , 2017, 92, 549-554.	2.0	24
264	Diagnosis and Management of Waldenström Macroglobulinemia. <i>JAMA Oncology</i> , 2017, 3, 1257.	3.4	110
265	Delineation of the timing of second-line therapy post autologous stem cell transplant in patients with AL amyloidosis. <i>Blood</i> , 2017, 130, 1578-1584.	0.6	21
266	A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2017, 52, 1372-1377.	1.3	13
267	Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. <i>British Journal of Haematology</i> , 2017, 178, 888-895.	1.2	15
268	Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation. <i>Haematologica</i> , 2017, 102, 1439-1445.	1.7	29
269	Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenström macroglobulinemia. <i>British Journal of Haematology</i> , 2017, 179, 98-105.	1.2	25
270	Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. <i>American Journal of Hematology</i> , 2017, 92, 1146-1155.	2.0	25

#	ARTICLE	IF	CITATIONS
271	Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 183-188.	1.4	4
272	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. <i>Blood</i> , 2017, 130, 1198-1204.	0.6	54
273	The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents. <i>Bone Marrow Transplantation</i> , 2017, 52, 34-40.	1.3	30
274	Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation. <i>American Journal of Hematology</i> , 2017, 92, 50-55.	2.0	41
275	Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression. <i>Leukemia</i> , 2017, 31, 130-135.	3.3	63
276	Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2017, 92, 908-917.	1.4	72
277	Tumour and immune cell dynamics explain the PSA bounce after prostate cancer brachytherapy. <i>British Journal of Cancer</i> , 2016, 115, 195-202.	2.9	35
278	Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light chain amyloidosis. <i>Cancer</i> , 2016, 122, 2197-2205.	2.0	37
279	Ontogenic growth as the root of fundamental differences between childhood and adult cancer. <i>Stem Cells</i> , 2016, 34, 543-550.	1.4	9
280	Autologous stem cell transplant for multiple myeloma patients 70 years or older. <i>Bone Marrow Transplantation</i> , 2016, 51, 1449-1455.	1.3	51
281	Proteasome inhibitor associated thrombotic microangiopathy. <i>American Journal of Hematology</i> , 2016, 91, E348-52.	2.0	95
282	Induction therapy pre autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. <i>American Journal of Hematology</i> , 2016, 91, 984-988.	2.0	45
283	Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. <i>Blood Cancer Journal</i> , 2016, 6, e454-e454.	2.8	56
284	Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. <i>Blood Cancer Journal</i> , 2016, 6, e512-e512.	2.8	38
285	Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. <i>Haematologica</i> , 2016, 101, 1102-1109.	1.7	9
286	Should tissue structure suppress or amplify selection to minimize cancer risk?. <i>Biology Direct</i> , 2016, 11, 41.	1.9	24
287	The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. <i>Leukemia Research</i> , 2016, 44, 32-39.	0.4	22
288	Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents. <i>Leukemia</i> , 2016, 30, 2208-2213.	3.3	87

#	ARTICLE	IF	CITATIONS
289	Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy. <i>Bone Marrow Transplantation</i> , 2016, 51, 1156-1158.	1.3	17
290	Myelomatous Involvement of the Central Nervous System. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 644-654.	0.2	38
291	Systemic Immunoglobulin Light Chain Amyloidosis—Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1354-1361.	1.4	43
292	Response to the Editor: On the Growth of Hematopoietic Stem Cells and Childhood Leukemias. <i>Stem Cells</i> , 2016, 34, 2610-2610.	1.4	0
293	Outcomes of patients with renal monoclonal immunoglobulin deposition disease. <i>American Journal of Hematology</i> , 2016, 91, 1123-1128.	2.0	76
294	Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. <i>American Journal of Hematology</i> , 2016, 91, 585-589.	2.0	57
295	N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2016, 91, 1129-1134.	2.0	71
296	IAP antagonists induce anti-tumor immunity in multiple myeloma. <i>Nature Medicine</i> , 2016, 22, 1411-1420.	15.2	133
297	Clinical characteristics and outcomes in biconal gammopathies. <i>American Journal of Hematology</i> , 2016, 91, 473-475.	2.0	30
298	Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatment. <i>Leukemia</i> , 2016, 30, 1079-1085.	3.3	32
299	The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1284-1289.	0.4	25
300	Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma. <i>Leukemia</i> , 2016, 30, 633-639.	3.3	57
301	Predictors of Early Relapse Following Initial Therapy for Systemic Immunoglobulin Light Chain Amyloidosis. <i>Blood</i> , 2016, 128, 2082-2082.	0.6	1
302	Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM). <i>Blood</i> , 2016, 128, 2968-2968.	0.6	4
303	Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom Macroglobulinemia. <i>Blood</i> , 2016, 128, 2972-2972.	0.6	2
304	Clinical Presentation and Outcomes of Patients with Light Chain Amyloidosis Who Have Non-Evaluable Free Light Chains at Diagnosis. <i>Blood</i> , 2016, 128, 3272-3272.	0.6	1
305	Bortezomib Versus Non-Bortezomib Based Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis. <i>Blood</i> , 2016, 128, 3317-3317.	0.6	3
306	Efficacy of Carfilzomib (K), Pomalidomide (P), and Dexamethasone (d) in Heavily Pretreated Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) in a Real World Setting. <i>Blood</i> , 2016, 128, 3337-3337.	0.6	5

#	ARTICLE	IF	CITATIONS
307	Practice Patterns of Re-Initiation of Therapy at Time of Relapse or Progression Post- Autologous Stem Cell Transplant (ASCT) Among Patients with AL Amyloidosis. <i>Blood</i> , 2016, 128, 3444-3444.	0.6	1
308	Effect of Standard Dose Versus Risk Adapted Melphalan Conditioning on Outcomes in Systemic AL Amyloidosis Patients Undergoing Frontline Autologous Stem Cell Transplant Based on Revised Mayo Stage. <i>Blood</i> , 2016, 128, 4627-4627.	0.6	1
309	Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study. <i>Blood</i> , 2016, 128, 491-491.	0.6	21
310	Phase 1/2 trial of ixazomib, cyclophosphamide, and dexamethasone for newly diagnosed multiple myeloma (NDMM).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8002-8002.	0.8	5
311	Quantification of circulating clonal plasma cells (cPCs) via multiparametric flow cytometry (MFC) to identify patients with smoldering multiple myeloma (SMM) at high risk of progression.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8015-8015.	0.8	1
312	Optimized Treatment Schedules for Chronic Myeloid Leukemia. <i>PLoS Computational Biology</i> , 2016, 12, e1005129.	1.5	13
313	The impact of novel induction regimens on transplant outcome in newly diagnosed multiple myeloma after controlling for high-risk FISH cytogenetics.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8033-8033.	0.8	0
314	Changes in serum alkaline phosphatase levels to predict response to ixazomib-based therapy in patients with newly diagnosed multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8053-8053.	0.8	0
315	Clinical utility of the revised international staging system (RISS) in newly diagnosed multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8017-8017.	0.8	0
316	Dexamethasone, rituximab and cyclophosphamide (DRC) in relapsed/refractory (R/R) and treatment naïve (TN) Waldenström macroglobulinemia (WM).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7552-7552.	0.8	1
317	Type 1 monoclonal cryoglobulinemia: Clinical presentation and outcomes.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8062-8062.	0.8	0
318	Immunoparesis in newly diagnosed AL amyloidosis as a marker for response and survival.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8016-8016.	0.8	0
319	A Risk Stratification Model Using Quantification of Circulating Plasma Cells in Multiple Myeloma Prior to Autologous Stem Cell Transplantation in the Era of Novel Agents. <i>Blood</i> , 2016, 128, 996-996.	0.6	0
320	Thyroid Functional Abnormalities in Newly Diagnosed AL Amyloidosis: Frequency and Influence By Type of Organ Involvement and Disease Burden. <i>Blood</i> , 2016, 128, 3273-3273.	0.6	0
321	Changes in Uninvolved Immunoglobulins during Multiple Myeloma Therapy. <i>Blood</i> , 2016, 128, 3251-3251.	0.6	0
322	Survival Trends in Young Patients with Waldenstrom Macroglobulinemia: Over 5 Decades of Experience. <i>Blood</i> , 2016, 128, 1810-1810.	0.6	0
323	Beta-Blockers Improved Survival Outcomes in Patients with Multiple Myeloma: A Retrospective Evaluation. <i>Blood</i> , 2016, 128, 3306-3306.	0.6	0
324	The Prognostic Significance of Polyclonal Bone Marrow Plasma Cells in Patients with Actively Relapsing Multiple Myeloma. <i>Blood</i> , 2016, 128, 1194-1194.	0.6	0

#	ARTICLE	IF	CITATIONS
325	Fluorescence in-Situ Hybridization (FISH) Analysis in Untreated AL Amyloidosis Has an Independent Prognostic Impact By Abnormality Type and Treatment Category. <i>Blood</i> , 2016, 128, 3269-3269.	0.6	0
326	Treatment Patterns and Outcomes Following Initial Relapse in Patients with Relapsed Systemic Immunoglobulin Light Chain Amyloidosis. <i>Blood</i> , 2016, 128, 3338-3338.	0.6	0
327	Outcome of Very Young (â‰‰ 40 years) Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Case Control Study. <i>Blood</i> , 2016, 128, 5576-5576.	0.6	0
328	Impact of Melphalan-Based Chemotherapy on Stem Cell Collection in Patients with Light Chain Amyloidosis. <i>Blood</i> , 2016, 128, 2187-2187.	0.6	0
329	Bortezomib, Melphalan and Low Dose TBI Conditioning for Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma. <i>Blood</i> , 2016, 128, 2267-2267.	0.6	0
330	Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. <i>American Journal of Hematology</i> , 2015, 90, 888-891.	2.0	18
331	Outcomes of primary refractory multiple myeloma and the impact of novel therapies. <i>American Journal of Hematology</i> , 2015, 90, 981-985.	2.0	38
332	Schnitzler syndrome: clinical features and histopathology. <i>Pathology and Laboratory Medicine International</i> , 2015, , 39.	0.2	3
333	Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2015, 5, e296-e296.	2.8	90
334	Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy. <i>Blood Cancer Journal</i> , 2015, 5, e364-e364.	2.8	81
335	Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. <i>American Journal of Hematology</i> , 2015, 90, 181-186.	2.0	76
336	Hematologic Characteristics of Proliferative Glomerulonephritides With Nonorganized Monoclonal Immunoglobulin Deposits. <i>Mayo Clinic Proceedings</i> , 2015, 90, 587-596.	1.4	92
337	Treatment of Immunoglobulin Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1054-1081.	1.4	106
338	Trends and Outcomes in Allogeneic Hematopoietic Stem Cell Transplant for Multiple Myeloma at Mayo Clinic. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 349-357.e2.	0.2	10
339	Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy. <i>Leukemia</i> , 2015, 29, 2033-2038.	3.3	25
340	Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death. <i>Blood Cancer Journal</i> , 2015, 5, e310-e310.	2.8	62
341	Soluble suppression of tumorigenicity 2 (s<sc>ST</sc>2), but not galactinâ€³, adds to prognostication in patients with systemic <sc>AL</sc> amyloidosis independent of <sc>NT</sc>â€pro<sc>BNP</sc> and troponin <sc>T</sc>. <i>American Journal of Hematology</i> , 2015, 90, 524-528.	2.0	31
342	In Patients with Light-Chain (AL) Amyloidosis Myocardial Contraction Fraction (MCF) Is a Simple, but Powerful Prognostic Measure That Can be Calculated from a Standard Echocardiogram (ECHO). <i>Blood</i> , 2015, 126, 1774-1774.	0.6	6

#	ARTICLE	IF	CITATIONS
343	Necrobiotic Xanthogranuloma (NXG) Associated with Monoclonal Gammopathies (MG): Clinical Features and Treatment Outcomes. <i>Blood</i> , 2015, 126, 1830-1830.	0.6	1
344	Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib. <i>Blood</i> , 2015, 126, 3050-3050.	0.6	8
345	Impact of Bone Marrow Plasmacytosis on Outcome in Patients with AL Amyloidosis Following Autologous Stem Cell Transplant. <i>Blood</i> , 2015, 126, 3177-3177.	0.6	3
346	Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic Experience. <i>Blood</i> , 2015, 126, 4197-4197.	0.6	5
347	Thrombotic Microangiopathy in Multiple Myeloma. <i>Blood</i> , 2015, 126, 5317-5317.	0.6	3
348	Reconstructing the in vivo dynamics of hematopoietic stem cells from telomere length distributions. <i>ELife</i> , 2015, 4, .	2.8	81
349	N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM). <i>Blood</i> , 2015, 126, 3292-3292.	0.6	0
350	Anti-Tumor Phagocytic Cell Activation in Multiple Myeloma By the IAP Antagonist LCL161: Results of a Phase II Clinical Trial. <i>Blood</i> , 2015, 126, 3039-3039.	0.6	0
351	AL Amyloidosis and Patient Reported Quality of Life. <i>Blood</i> , 2015, 126, 3317-3317.	0.6	0
352	The Impact of Induction Regimen Choice on Transplant Outcome and Survival in Newly Diagnosed Multiple Myeloma in the Era of Novel Agents. <i>Blood</i> , 2015, 126, 3044-3044.	0.6	0
353	Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy. <i>Bone Marrow Transplantation</i> , 2014, 49, 201-205.	1.3	20
354	Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. <i>American Journal of Hematology</i> , 2014, 89, 1051-1054.	2.0	32
355	High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis. <i>Heart</i> , 2014, 100, 383-388.	1.2	63
356	Imaging findings in 22 cases of Schnitzler syndrome: characteristic para-articular osteosclerosis, and the "hot knees" sign differential diagnosis. <i>Skeletal Radiology</i> , 2014, 43, 905-915.	1.2	30
357	Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. <i>Leukemia</i> , 2014, 28, 1122-1128.	3.3	1,128
358	Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant. <i>European Journal of Haematology</i> , 2014, 92, 485-490.	1.1	23
359	Dynamics of Leukemia Stem-like Cell Extinction in Acute Promyelocytic Leukemia. <i>Cancer Research</i> , 2014, 74, 5386-5396.	0.4	25
360	The ecology of cancer from an evolutionary game theory perspective. <i>Interface Focus</i> , 2014, 4, 20140019.	1.5	68

#	ARTICLE	IF	CITATIONS
361	Biomedical System Dynamics to Improve Anemia Control With Darbepoetin Alfa in Long-Term Hemodialysis Patients. Mayo Clinic Proceedings, 2014, 89, 87-94.	1.4	285
362	Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy. Mayo Clinic Proceedings, 2014, 89, 926-933.	1.4	240
363	How we manage autologous stem cell transplantation for patients with multiple myeloma. Blood, 2014, 124, 882-890.	0.6	85
364	Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood, 2014, 124, 907-912.	0.6	111
365	Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM). Blood, 2014, 124, 304-304.	0.6	25
366	Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. Mayo Clinic Proceedings, 2013, 88, 360-376.	1.4	440
367	Second auto-SCT for treatment of relapsed multiple myeloma. Bone Marrow Transplantation, 2013, 48, 568-573.	1.3	59
368	Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center.. Bone Marrow Transplantation, 2013, 48, 1302-1307.	1.3	74
369	On the dynamics of neutral mutations in a mathematical model for a homogeneous stem cell population. Journal of the Royal Society Interface, 2013, 10, 20120810.	1.5	31
370	Coexistent Multiple Myeloma or Increased Bone Marrow Plasma Cells Define Equally High-Risk Populations in Patients With Immunoglobulin Light Chain Amyloidosis. Journal of Clinical Oncology, 2013, 31, 4319-4324.	0.8	193
371	A deterministic model for the occurrence and dynamics of multiple mutations in hierarchically organized tissues. Journal of the Royal Society Interface, 2013, 10, 20130349.	1.5	45
372	Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplantation, 2013, 48, 557-561.	1.3	158
373	Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma. Journal of Clinical Oncology, 2013, 31, 4529-4535.	0.8	147
374	Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma. Leukemia, 2013, 27, 2062-2066.	3.3	30
375	Schnitzler syndrome: an under-diagnosed clinical entity. Haematologica, 2013, 98, 1581-1585.	1.7	42
376	Survival Outcomes Of Very Young (<40 years) Myeloma Patients. Blood, 2013, 122, 2136-2136.	0.6	3
377	Genomics Of Familial Myelodysplastic Syndromes and Acute Myeloid Leukemia. Blood, 2013, 122, 2803-2803.	0.6	2
378	Soluble ST2 (sST2) Is a Novel Valuable Prognostic Marker Among Patients With Immunoglobulin Light Chain (AL) Amyloidosis. Blood, 2013, 122, 3095-3095.	0.6	1

#	ARTICLE	IF	CITATIONS
379	Therapy Related MDS/AML In Multiple Myeloma Patients In The Era Of Novel Agents. Blood, 2013, 122, 3117-3117.	0.6	2
380	Myelomatous Involvement Of The Central Nervous System: Mayo Clinic Experience. Blood, 2013, 122, 3119-3119.	0.6	3
381	Impact Of FISH Abnormalities On Response To Lenalidomide In Patients With Multiple Myeloma. Blood, 2013, 122, 3210-3210.	0.6	7
382	Lenalidomide Maintenance Therapy In Multiple Myeloma: A Meta-Analysis Of Randomized Trials. Blood, 2013, 122, 407-407.	0.6	12
383	Autologous Stem Cell Transplantation In Immunoglobulin Light Chain Amyloidosis With Factor X Deficien. Blood, 2013, 122, 2151-2151.	0.6	9
384	Familial Myeloid Neoplasms: Clinical Spectrum and Associated Abnormalities. Blood, 2013, 122, 2794-2794.	0.6	0
385	Effect Of Immediate Prior-Line Lenalidomide Or Thalidomide Therapy On Response To Pomalidomide In Multiple Myeloma. Blood, 2013, 122, 1979-1979.	0.6	0
386	Long Term Response To Lenalidomide With and Without Continuous Therapy Among Patients With Newly Diagnosed Multiple Myeloma. Blood, 2013, 122, 3209-3209.	0.6	0
387	Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements. Journal of Clinical Oncology, 2012, 30, 989-995.	0.8	837
388	Pinhole micro-SPECT/CT for noninvasive monitoring and quantitation of oncolytic virus dispersion and percent infection in solid tumors. Gene Therapy, 2012, 19, 279-287.	2.3	27
389	Dynamics of melanoma tumor therapy with vesicular stomatitis virus: explaining the variability in outcomes using mathematical modeling. Gene Therapy, 2012, 19, 543-549.	2.3	27
390	Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood, 2012, 119, 5397-5404.	0.6	144
391	Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood, 2012, 119, 4860-4867.	0.6	119
392	Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood, 2012, 119, 2100-2105.	0.6	218
393	Monitoring the initial delivery of an oncolytic measles virus encoding the human sodium iodide symporter to solid tumors using contrast-enhanced computed tomography. Journal of Gene Medicine, 2012, 14, 590-597.	1.4	12
394	Evolutionary Dynamics of Mutations in Hematopoietic Stem Cells and Beyond. , 2012, , 115-123.		0
395	A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. British Journal of Haematology, 2012, 156, 326-333.	1.2	48
396	Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. Cancer, 2012, 118, 1585-1592.	2.0	106

#	ARTICLE	IF	CITATIONS
397	Outcomes and Treatments of Relapsed AL Amyloidosis Following Stem Cell Transplant. <i>Blood</i> , 2012, 120, 1858-1858.	0.6	2
398	Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Myeloma: Long Term Follow up and Factors Predicting Outcome in 345 Patients. <i>Blood</i> , 2012, 120, 201-201.	0.6	16
399	Doxycycline Used As Post Transplant Antibacterial Prophylaxis Improves Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Stem Cell Transplantation.. <i>Blood</i> , 2012, 120, 3138-3138.	0.6	26
400	Continued Improvement in Survival in Multiple Myeloma and the Impact of Novel Agents. <i>Blood</i> , 2012, 120, 3972-3972.	0.6	7
401	Survival After Second, Third, and Fourth Line Therapy Better Than Expected in Patients with Previously Treated AL Amyloidosis Who Were Not Transplant Candidates At Diagnosis.. <i>Blood</i> , 2012, 120, 946-946.	0.6	1
402	Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma.. <i>Blood</i> , 2012, 120, 2973-2973.	0.6	16
403	Outcomes of Patients with POEMS Syndrome Treated Initially with Radiation. <i>Blood</i> , 2012, 120, 448-448.	0.6	0
404	Patients with Immunoglobulin Light Chain Amyloidosis (AL) Undergoing High Dose Chemotherapy with Autologous Stem Cell Transplantation (ASCT) have Superior Outcomes As Compared to Patients with Multiple Myeloma (MM). <i>Blood</i> , 2012, 120, 600-600.	0.6	0
405	Refinement in Patient Selection to Reduce Treatment-Related Mortality From Stem Cell Transplantation in Amyloidosis. <i>Blood</i> , 2012, 120, 599-599.	0.6	0
406	Importance of Achieving Sustained Stringent Complete Response (sCR) Following Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , 2012, 120, 1988-1988.	0.6	0
407	Recent Improvements in Survival in Primary Systemic Amyloidosis and the Importance of an Early Mortality Risk Score. <i>Mayo Clinic Proceedings</i> , 2011, 86, 12-18.	1.4	164
408	Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. <i>Leukemia</i> , 2011, 25, 689-696.	3.3	104
409	Stochastic dynamics and the evolution of mutations in stem cells. <i>BMC Biology</i> , 2011, 9, 41.	1.7	20
410	Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial. <i>American Journal of Hematology</i> , 2011, 86, 640-645.	2.0	57
411	Modelling hematopoiesis in health and disease. <i>Mathematical and Computer Modelling</i> , 2011, 53, 1546-1557.	2.0	16
412	Explaining the in vitro and in vivo differences in leukemia therapy. <i>Cell Cycle</i> , 2011, 10, 1540-1544.	1.3	7
413	Dynamics of Mutant Cells in Hierarchical Organized Tissues. <i>PLoS Computational Biology</i> , 2011, 7, e1002290.	1.5	70
414	The Utility of High Sensitivity Cardiac Troponin Among Patients with Immunoglobulin Light Chain Amyloidosis. <i>Blood</i> , 2011, 118, 2887-2887.	0.6	1

#	ARTICLE	IF	CITATIONS
415	Long Term Outcomes of Pomalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma: Analysis 4 Years After the Original Cohort. <i>Blood</i> , 2011, 118, 2942-2942.	0.6	2
416	Survival Outcome of Young Multiple Myeloma (MM) Patients in the Era of Novel Therapies. <i>Blood</i> , 2011, 118, 2950-2950.	0.6	1
417	A Phase I Trial of Zevalin Radioimmunotherapy with High-Dose Melphalan (HDM) and Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma (MM). <i>Blood</i> , 2011, 118, 3095-3095.	0.6	1
418	Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of 225 Patients Treated in Five Cohorts Over Three Years,. <i>Blood</i> , 2011, 118, 3963-3963.	0.6	4
419	Factors Predicting Early Mortality in Patients with Newly Diagnosed Multiple Myeloma,. <i>Blood</i> , 2011, 118, 3981-3981.	0.6	3
420	The Timing of Acute Renal Failure Strongly Affects Survival of Immunoglobulin Light Chain (AL) Amyloidosis Patients Undergoing Autologous Stem Cell Transplantation,. <i>Blood</i> , 2011, 118, 4120-4120.	0.6	5
421	Relapse of POEMS Following Autologous Stem Cell Transplantation: A Single Center Experience. <i>Blood</i> , 2011, 118, 3101-3101.	0.6	0
422	Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide-Based Initial Therapy. <i>Blood</i> , 2011, 118, 2992-2992.	0.6	0
423	The Depth of Renal Response Strongly Predicts Overall Survival in Patients with AL Amyloidosis. <i>Blood</i> , 2011, 118, 2868-2868.	0.6	8
424	Matched Case Control Analysis Comparing Long Term Survival of Multiple Myeloma Patients Who Received Stem Cell Transplant with and without Idiotype-Pulsed Dendritic Cell Vaccine. <i>Blood</i> , 2011, 118, 636-636.	0.6	0
425	IgD Amyloidosis: An Unrecognized Entity. <i>Blood</i> , 2011, 118, 5079-5079.	0.6	0
426	Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells. <i>Haematologica</i> , 2010, 95, 900-907.	1.7	55
427	Optimization of Virotherapy for Cancer. <i>Bulletin of Mathematical Biology</i> , 2010, 72, 469-489.	0.9	41
428	Somatic mutations and the hierarchy of hematopoiesis. <i>BioEssays</i> , 2010, 32, 1003-1008.	1.2	24
429	How best to use new therapies in multiple myeloma. <i>Blood Reviews</i> , 2010, 24, 91-100.	2.8	11
430	Modeling the architecture and dynamics of hematopoiesis. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2010, 2, 235-244.	6.6	23
431	Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). <i>Leukemia</i> , 2010, 24, 1934-1939.	3.3	182
432	Oncolytic measles viruses encoding interferon β and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. <i>Cancer Gene Therapy</i> , 2010, 17, 550-558.	2.2	112

#	ARTICLE	IF	CITATIONS
433	Mutations in the Stalk Region of the Measles Virus Hemagglutinin Inhibit Syncytium Formation but Not Virus Entry. <i>Journal of Virology</i> , 2010, 84, 10913-10917.	1.5	10
434	Stem cell transplantation in patients with autonomic neuropathy due to primary (AL) amyloidosis. <i>Neurology</i> , 2010, 74, 913-918.	1.5	30
435	Sodium Iodide Symporter (<i>NIS</i>)-Mediated Radiotherapy for Pancreatic Cancer. <i>American Journal of Roentgenology</i> , 2010, 195, 341-349.	1.0	69
436	Evolutionary Dynamics of Chronic Myeloid Leukemia. <i>Genes and Cancer</i> , 2010, 1, 309-315.	0.6	17
437	Death by fusion for acute leukemia cells. <i>Cancer Biology and Therapy</i> , 2010, 9, 358-361.	1.5	2
438	Evolutionary dynamics of two related malignant plasma cell lines. <i>Cell Cycle</i> , 2010, 9, 3816-3821.	1.3	6
439	A promising approach for treatment of tumor-induced bone diseases: Utilizing bisphosphonate derivatives of nucleoside antimetabolites. <i>Bone</i> , 2010, 47, 12-22.	1.4	34
440	Reproductive fitness advantage of BCRÁABL expressing leukemia cells. <i>Cancer Letters</i> , 2010, 294, 43-48.	3.2	12
441	In silico evolutionary dynamics of tumour virotherapy. <i>Integrative Biology (United Kingdom)</i> , 2010, 2, 41-45.	0.6	21
442	Efficacy of Retreatment with Immunomodulatory Compounds In Patients Receiving Initial Therapy for Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2010, 116, 1964-1964.	0.6	5
443	Transplantation for Immunoglobulin Light Chain Amyloidosis. A Statistical Analysis of Factors Predicting Outcome In Over 400 Patients. <i>Blood</i> , 2010, 116, 3557-3557.	0.6	1
444	Pre-Stem Cell Transplant Induction Therapy Does Not Affect Post-Transplant Survival In Light Chain (AL) Amyloidosis. <i>Blood</i> , 2010, 116, 370-370.	0.6	4
445	Pomalidomide Plus Low-Dose Dexamethasone In Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies In Dual-Refractory Disease. <i>Blood</i> , 2010, 116, 863-863.	0.6	1
446	Response to Salvage Therapies and Outcome of Patients with Multiple Myeloma Relapsing After Pomalidomide Therapy. <i>Blood</i> , 2010, 116, 1965-1965.	0.6	0
447	Collection of Stem Cell Early In the Disease Course of Multiple Myeloma Is Associated with Early Engraftment.. <i>Blood</i> , 2010, 116, 4518-4518.	0.6	0
448	Risk Score at Diagnosis and the Dynamics of Response to TKI Therapy In Chronic Myeloid Leukemia.. <i>Blood</i> , 2010, 116, 1236-1236.	0.6	0
449	Peripheral Blood Stem Cell Collection In Patients Undergoing Induction Therapy with Lenalidomide Based Regimens: Failure Rates and Salvage Approaches. <i>Blood</i> , 2010, 116, 2253-2253.	0.6	5
450	Improvement In Renal Function In Newly Diagnosed Myeloma Improves Survival, but Still Remains Inferior to Those with Normal Renal Function. <i>Blood</i> , 2010, 116, 2970-2970.	0.6	1

#	ARTICLE	IF	CITATIONS
451	A Phase-2 Study of Pomalidomide and Dexamethasone In Previously-Treated Light-Chain (AL) Amyloidosis. <i>Blood</i> , 2010, 116, 987-987.	0.6	1
452	Five-Year Follow-up of Randomized, Phase II Trial of Idiotype-Pulsed Dendritic Cell Vaccine with Adjuvant Cytokines In Plateau Phase and Post-Transplant Multiple Myeloma. <i>Blood</i> , 2010, 116, 1958-1958.	0.6	0
453	Trend towards Improved Day 100 and 2-Year Survival After SCT for AL Amyloidosis: Outcomes Before and After 2006. <i>Blood</i> , 2010, 116, 3554-3554.	0.6	13
454	IDH Mutations and Trisomy 8 In Myelodysplastic Syndromes and Acute Myeloid Leukemia. <i>Blood</i> , 2010, 116, 4009-4009.	0.6	0
455	Stem Cell Transplant without Growth Factor In Multiple Myeloma: Engraftment Kinetics, Bacteremia, and Hospitalization.. <i>Blood</i> , 2010, 116, 3469-3469.	0.6	0
456	Comparison of Troponin T and N-Terminal-Pro-Brain Natriuretic Peptides In Two Models of Treatment Related Mortality In AL Amyloidosis Patients Following Autologous Stem Cell Transplantation. <i>Blood</i> , 2010, 116, 3572-3572.	0.6	6
457	Reply: Evolutionary game theory: lessons and limitations, a cancer perspective. <i>British Journal of Cancer</i> , 2009, 101, 2062-2063.	2.9	4
458	Quantitative Molecular Imaging of Viral Therapy for Pancreatic Cancer Using an Engineered Measles Virus Expressing the Sodium-Iodide Symporter Reporter Gene. <i>American Journal of Roentgenology</i> , 2009, 192, 279-287.	1.0	70
459	Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2009, 27, 5008-5014.	0.8	286
460	Cyclic neutropenia in animals. <i>American Journal of Hematology</i> , 2009, 84, 258-258.	2.0	15
461	Progenitor cell self-renewal and cyclic neutropenia. <i>Cell Proliferation</i> , 2009, 42, 330-338.	2.4	24
462	Dynamics of multiple myeloma tumor therapy with a recombinant measles virus. <i>Cancer Gene Therapy</i> , 2009, 16, 873-882.	2.2	60
463	Cancer phenotype as the outcome of an evolutionary game between normal and malignant cells. <i>British Journal of Cancer</i> , 2009, 101, 1130-1136.	2.9	101
464	The allometry of chronic myeloid leukemia. <i>Journal of Theoretical Biology</i> , 2009, 259, 635-640.	0.8	10
465	Clinical Outcomes With and Without Sargramostim (GM-CSF) Post Autologous Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 43.	2.0	1
466	Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple myeloma. <i>Leukemia and Lymphoma</i> , 2009, 50, 781-787.	0.6	6
467	Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines. <i>Mayo Clinic Proceedings</i> , 2009, 84, 1095-1110.	1.4	389
468	Melphalan and Prednisone (MP) Versus Melphalan, Prednisone and Thalidomide (MPT) as Initial Therapy for Previously Untreated Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials.. <i>Blood</i> , 2009, 114, 615-615.	0.6	6

#	ARTICLE	IF	CITATIONS
469	Novel Agents for Initial Therapy of Multiple Myeloma: Comparable Results with Continued Initial Therapy and Delayed Transplantation at Relapse Versus Early Transplantation.. Blood, 2009, 114, 956-956.	0.6	1
470	Superiority of Lenalidomide-Dexamethasone Versus Thalidomide-Dexamethasone as Initial Therapy for Newly Diagnosed Multiple Myeloma.. Blood, 2009, 114, 3884-3884.	0.6	0
471	Emerging therapies for multiple myeloma. Oncology, 2009, 23, 407-15.	0.4	5
472	Modeling of cancer virotherapy with recombinant measles viruses. Journal of Theoretical Biology, 2008, 252, 109-122.	0.8	131
473	Some Dynamic Aspects of Hematopoietic Stem Cells. Stem Cell Reviews and Reports, 2008, 4, 57-64.	5.6	1
474	Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis. American Journal of Hematology, 2008, 83, 614-617.	2.0	123
475	Cyclic neutropenia in mammals. American Journal of Hematology, 2008, 83, 920-921.	2.0	18
476	Successful Cancer Treatment: Eradication of Cancer Stem Cells. , 2008, , 179-191.		0
477	Autologous Stem Cell Transplant in 716 Patients With Multiple Myeloma: Low Treatment-Related Mortality, Feasibility of Outpatient Transplant, and Effect of a Multidisciplinary Quality Initiative. Mayo Clinic Proceedings, 2008, 83, 1131-1135.	1.4	90
478	Chronic Myeloid Leukemia: Origin, Development, Response to Therapy, and Relapse. Clinical Leukemia, 2008, 2, 133-139.	0.2	30
479	Neutral evolution in paroxysmal nocturnal hemoglobinuria. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 18496-18500.	3.3	46
480	Improved survival in multiple myeloma and the impact of novel therapies. Blood, 2008, 111, 2516-2520.	0.6	2,022
481	Dynamics of haemopoiesis across mammals. Proceedings of the Royal Society B: Biological Sciences, 2008, 275, 2389-2392.	1.2	16
482	Multiple mutant clones in blood rarely coexist. Physical Review E, 2008, 77, 021915.	0.8	20
483	Plasma membrane phospholipid labeling to estimate tumor burden and kinetics. Cancer Biology and Therapy, 2008, 7, 748-749.	1.5	0
484	Comparison of High-Dose Cyclophosphamide and Growth Factor with Growth Factor Alone for Mobilization of Stem Cells for Transplantation in Patients with Multiple Myeloma.. Blood, 2008, 112, 2301-2301.	0.6	0
485	(A)Symmetric Stem Cell Replication and Cancer. PLoS Computational Biology, 2007, 3, e53.	1.5	104
486	Genetic Progression and the Waiting Time to Cancer. PLoS Computational Biology, 2007, 3, e225.	1.5	337

#	ARTICLE	IF	CITATIONS
487	The emergence of tumor metastases. <i>Cancer Biology and Therapy</i> , 2007, 6, 383-390.	1.5	25
488	Ontogenic growth of the haemopoietic stem cell pool in humans. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2007, 274, 2497-2501.	1.2	24
489	Relationship Between Depth of Response and Outcome in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2007, 25, 4933-4937.	0.8	40
490	Acquired hematopoietic stem-cell disorders and mammalian size. <i>Blood</i> , 2007, 110, 4120-4122.	0.6	18
491	Stochastic Dynamics of Hematopoietic Tumor Stem Cells. <i>Cell Cycle</i> , 2007, 6, 461-466.	1.3	88
492	Imatinib and Type 2 Diabetes. <i>Endocrine Practice</i> , 2007, 13, 126-130.	1.1	25
493	On the Origin of Multiple Mutant Clones in Paroxysmal Nocturnal Hemoglobinuria. <i>Stem Cells</i> , 2007, 25, 3081-3084.	1.4	31
494	Preclinical Pharmacology and Toxicology of Intravenous MV-NIS, an Oncolytic Measles Virus Administered With or Without Cyclophosphamide. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 82, 700-710.	2.3	117
495	A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. <i>Leukemia</i> , 2007, 21, 529-534.	3.3	191
496	In Vivo and In Silico Studies on single versus multiple transplants for multiple myeloma. <i>Cancer Science</i> , 2007, 98, 734-739.	1.7	6
497	Serum M-spike and transplant outcome in patients with multiple myeloma. <i>Cancer Science</i> , 2007, 98, 1035-1040.	1.7	15
498	A Microenvironment Based Model of Antimitotic Therapy of Gompertzian Tumor Growth. <i>Bulletin of Mathematical Biology</i> , 2007, 69, 1691-1708.	0.9	16
499	14q32 Abnormalities and 13q Deletions Are Common in Primary Systemic Amyloidosis Using Cytoplasmic Immunoglobulin Fluorescence In Situ Hybridization (cIg-FISH). <i>Blood</i> , 2007, 110, 2477-2477.	0.6	1
500	Compartmental Architecture and Dynamics of Hematopoiesis. <i>PLoS ONE</i> , 2007, 2, e345.	1.1	91
501	Pre-Clinical Data and Preliminary Patient Results of Intravenous MV-NIS To Treat Relapsed, Refractory Multiple Myeloma. <i>Blood</i> , 2007, 110, 1181-1181.	0.6	0
502	Melphalan and Dexamethasone Is an Effective Therapy for Primary Systemic Amyloidosis. <i>Blood</i> , 2007, 110, 3608-3608.	0.6	0
503	Increased Cytotoxic T-Cell Infiltrates in the Bone Marrow Is an Independent Adverse Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2007, 110, 1492-1492.	0.6	0
504	Engraftment Syndrome Is Common in Patients with POEMS Syndrome Undergoing PBSCT. <i>Blood</i> , 2007, 110, 2995-2995.	0.6	0

#	ARTICLE	IF	CITATIONS
505	Cyclophosphamide Mobilization Does Not Improve Outcome in Patients Receiving Stem Cell Transplantation for Multiple Myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2006, 6, 384-388.	1.4	79
506	Mathematical modeling of cancer radiotherapy. <i>Mathematical Biosciences</i> , 2006, 199, 55-78.	0.9	114
507	Allometric Scaling of the Active Hematopoietic Stem Cell Pool across Mammals. <i>PLoS ONE</i> , 2006, 1, e2.	1.1	86
508	Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system. <i>Blood</i> , 2006, 107, 3384-3388.	0.6	64
509	Immunoglobulin free light chains and solitary plasmacytoma of bone. <i>Blood</i> , 2006, 108, 1979-1983.	0.6	152
510	Successful Therapy Must Eradicate Cancer Stem Cells. <i>Stem Cells</i> , 2006, 24, 2603-2610.	1.4	216
511	Combined I-124 Positron Emission Tomography/Computed Tomography Imaging of NIS Gene Expression in Animal Models of Stably Transfected and Intravenously Transfected Tumor. <i>Molecular Imaging and Biology</i> , 2006, 8, 16-23.	1.3	61
512	Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia. <i>Cancer</i> , 2006, 106, 623-630.	2.0	56
513	Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis. <i>Cancer</i> , 2006, 106, 1985-1989.	2.0	58
514	Single Versus Multiple Transplants for Multiple Myeloma: Insights from In Vivo and In Silico Studies.. <i>Blood</i> , 2006, 108, 5452-5452.	0.6	0
515	The Serum M-Spike and Transplant Outcome in Patients with Multiple Myeloma.. <i>Blood</i> , 2006, 108, 5441-5441.	0.6	0
516	Monocytosis Is an Independent Risk Factor for Survival in Agnogenic Myeloid Metaplasia.. <i>Blood</i> , 2006, 108, 3629-3629.	0.6	0
517	Der(6)t(1;6)(q21-23;p21.3): a specific cytogenetic abnormality in myelofibrosis with myeloid metaplasia. <i>British Journal of Haematology</i> , 2005, 130, 229-232.	1.2	47
518	Focal and Segmental Glomerulosclerosis and Plasma Cell Proliferative Disorders. <i>American Journal of Kidney Diseases</i> , 2005, 46, 278-282.	2.1	49
519	A critical review of anagrelide therapy in essential thrombocythemia and related disorders. <i>Leukemia and Lymphoma</i> , 2005, 46, 641-650.	0.6	21
520	Interaction of measles virus vectors with Auger electron emitting radioisotopes. <i>Biochemical and Biophysical Research Communications</i> , 2005, 337, 22-29.	1.0	32
521	Immunoglobulin Free Light Chains at Diagnosis: Predictors of Progression and Survival in Solitary Plasmacytoma of Bone.. <i>Blood</i> , 2005, 106, 5080-5080.	0.6	1
522	Flow Cytometric Detection of Circulating Myeloma Cells Pretransplant in Patients with Multiple Myeloma: A Simple Risk Stratification System.. <i>Blood</i> , 2005, 106, 1164-1164.	0.6	7

#	ARTICLE	IF	CITATIONS
523	Presence of Unfavorable Cytogenetic Abnormalities Is the Strongest Predictor of Poor Survival in Secondary Myelofibrosis.. Blood, 2005, 106, 2585-2585.	0.6	0
524	Microcytosis in Myelofibrosis with Myeloid Metaplasia: Prevalence and Clinical Correlates.. Blood, 2005, 106, 4947-4947.	0.6	0
525	Cyclophosphamide Mobilization Does Not Improve Outcome in Patients Transplanted for Multiple Myeloma.. Blood, 2005, 106, 1165-1165.	0.6	0
526	Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial. Haematologica, 2005, 90, 1650-4.	1.7	21
527	Anagrelide: an update on its mechanisms of action and therapeutic potential. Expert Review of Anticancer Therapy, 2004, 4, 533-541.	1.1	4
528	Dynamic iodide trapping by tumor cells expressing the thyroidal sodium iodide symporter. Biochemical and Biophysical Research Communications, 2004, 325, 157-166.	1.0	39
529	Image-guided radiotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood, 2004, 103, 1641-1646.	0.6	306
530	Myelofibrosis with Myeloid Metaplasia: New Developments in Pathogenesis and Treatment. Internal Medicine, 2004, 43, 540-547.	0.3	38
531	Prognostic Diversity of Cytogenetic Lesions in Myelofibrosis with Myeloid Metaplasia: A Prospective Study of 88 Patients.. Blood, 2004, 104, 1508-1508.	0.6	0
532	Oncolytic Measles Virus Selectively Targets CD46 Overexpression on Myeloma Cells.. Blood, 2004, 104, 2392-2392.	0.6	0
533	In vivo imaging and tumor therapy with the sodium iodide symporter. Journal of Cellular Biochemistry, 2003, 90, 1079-1086.	1.2	81
534	Genetic Targeting of Retroviral Vectors. , 2003, , 267-291.		4
535	Genetically targeted radiotherapy for multiple myeloma. Blood, 2003, 102, 489-496.	0.6	92
536	Continuous factor VIII infusion therapy in patients with haemophilia A undergoing surgical procedures with plasma-derived or recombinant factor VIII concentrates. Haemophilia, 2002, 8, 629-634.	1.0	50
537	Promising preclinical activity of 2-methoxyestradiol in multiple myeloma. Clinical Cancer Research, 2002, 8, 3948-54.	3.2	39
538	Unexplained Pulmonary Hypertension in Chronic Myeloproliferative Disorders. Chest, 2001, 120, 801-808.	0.4	168